Drug intelligence / Profile preview

allopurinol

Development stage: Approved
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Allopurinol is a small molecule pharmaceutical drug classified as a xanthine oxidase inhibitor. It is primarily used to reduce the production of uric acid in the body by inhibiting the enzyme xanthine oxidase, which converts hypoxanthine to xanthine and then to uric acid. This mechanism lowers serum and urinary uric acid concentrations. Allopurinol is indicated for the management of gout (including acute attacks, tophi, joint destruction), prevention of recurrent calcium oxalate kidney stones in patients with high uric acid excretion, and for controlling hyperuricemia associated with cancer therapy (tumor lysis syndrome) in leukemia, lymphoma, and solid tumor malignancies[1][2][4][7]. The drug was first approved by the FDA in 1966.

Brand names: ZyloprimAloprimLopurin
Other names: 别嘌醇别嘌呤醇异嘌呤醇

Targets

XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on allopurinol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on allopurinol.